XENENasdaqPharmaceutical PreparationsFiscal year ends December 31

Xenon Pharmaceuticals Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$35.08+1.59 (+4.75%)

Close on Oct 19, 2026

Market cap: $3.49B
P/E (TTM): –
Dividend yield: –

Xenon Pharmaceuticals Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31
Revenue	7.50	0	0	9.43	18	32	6.83	–	0.31	1.80	16	28	27	14
Research & Development	301	210	168	106	75	51	39	24	26	20	15	12	12	10
General & Administrative	80	69	47	33	22	13	11	8.41	7.31	6.79	9.79	5.50	5.34	7.01
Operating Expenses	381	279	214	139	97	63	50	38	33	27	25	17	18	17
Operating Income	-373	-279	-214	-129	-79	-31	-43	-38	-33	-25	-9.36	11	9.71	-3.15
Interest Expense	–	–	–	–	–	0.48	1.43	1.39	–	–	–	–	0.06	0.09
Interest & Investment Income	27	42	28	8.71	0.47	2.28	2.35	1.22	0.48	0.50	0.54	0.57	0.34	0.14
Other Non-Operating Income	28	41	31	3.89	0.11	2.21	–	–	–	–	–	–	–	–
Asset Impairment Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	–
Pretax Income	-345	-238	-183	-125	-79	-29	-42	-35	–	–	–	–	–	–
Income Tax Expense	1.02	-4.09	-0.29	0.12	-0.01	-0.26	-0.02	-0.02	–	–	–	0	0	0
Net Income incl. Noncontrolling Interests	-346	-234	-182	-125	-79	-29	-42	-34	-31	–	–	–	–	–
Net Income	-346	-234	-182	-125	-79	-29	-42	-34	-31	-23	-16	13	12	-4.30
Net Income to Common	–	-234	-182	-125	-77	-28	-40	-32	-31	-23	-16	13	3.83	-4.30
EPS (Basic)(per share)	-4.36	-3.01	-2.73	-2.06	-1.77	-0.81	-1.54	-1.63	-1.71	-1.48	-1.10	4.11	2.87	-3.24
EPS (Diluted)(per share)	-4.36	-3.01	-2.73	-2.06	-1.77	-0.81	-1.54	-1.63	-1.72	-1.48	-1.10	3.28	1.91	-3.24
Shares Outstanding (Basic, Weighted)(shares)	79	78	67	61	44	35	26	19	18	15	14	3.17	1.34	1.33
Shares Outstanding (Diluted, Weighted)(shares)	79	78	67	61	44	35	26	19	18	15	14	3.96	2.01	1.33
EBITDA	-371	-277	-212	-128	-78	-31	-42	-37	-32	-24	-8.32	12	10	-2.37

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -51.8%

Financial strength

Current ratio: 21.02
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 265.6%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 2.81
Dividend yield: –